The Role of Focal Approach as Alternative to Nephron-Sparing Surgery in the Treatment of Stage I Cancer in Renal Graft: Results of a Systematic Review

Alessandro POSA,1 Valentina LANCELLOTTA,2 Filippo PAOLETTI,3 Alessandro TANZILLI,1 Anna ACAMPORA,4,5 Barbara Alicja JERECZEK-FOSSA,6,7 Maria Antonietta GAMBACORTA,2,3 Jacopo ROMAGNOLI,8 Rosario Francesco GRASSO,9 Andrea VELTRI,10 György KOVACS,2 Vincenzo VALENTINI,2,3 Riccardo MANFREDI,1,3 Roberto IEZZI,1 Luca TAGLIAFERRI2

1Department of Diagnostic Imaging, Fondazione Policlinico Universitario A. Gemelli IRCCS, Radiation Oncology and Hematology, U.O.C. of Diagnostic and General Interventional Radiology, Rome-Italy
2Department of Diagnostic Imaging, Fondazione Policlinico Universitario A. Gemelli IRCCS, Radiation Oncology and Hematology, U.O.C. of Radiation Oncology Therapy, Rome-Italy
3Sacred Heart Catholic University, Institute of Radiology, Rome-Italy
4Department of Epidemiology of the Regional Health Service of Lazio, UOC Epidemiology of the State of Health of the Population, Rome-Italy
5Catholic University of the Sacred Heart, Institute of Public Health, Section of Hygiene, Rome-Italy
6Department of Oncology and Hemato-oncology, University of Milan, Milan-Italy
7Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan-Italy
8Renal Transplant Unit, University Hospital A. Gemelli IRCCS, Rome-Italy
9Unit of Diagnostic Imaging, Università Campus Bio-Medico of Rome, Rome-Italy
10Institute of Radiology, University of Turin, Turin-Italy

SUMMARY
In patients with kidney graft neoplasms, the treatment of choice is still represented by surgical approach, mainly based on partial nephrectomy/nephron sparing surgery (NSS). In this oncologic setting, focal treatments (FT) are becoming more and more useful to avoid the risk of dialysis, considering graft viability of utmost importance. There is still little evidence on which is the best FT option in kidney graft neoplasms and on its therapeutic indications. We performed a systematic review to assess the role of FT such as thermal ablation, interventional radiotherapy, electrochemotherapy, and stereotactic body radiotherapy, as alternative to NSS in the treatment of Stage I kidney cancer. We searched PubMed, Scopus, and Web of Science for articles published between 2010 and 2020 focusing on kidney transplant recipients with kidney graft neoplasm who had undergone FT. The review is framed by the population, intervention, control, and outcomes criteria. The studies underlined safety and efficacy of FT, with low morbidity and good graft survival, but none of them provided a direct comparison with graft nephrectomy or NSS. There is still no clear evidence that FTs, and percutaneous ones in particular, are indicated as a standard treatment in kidney graft neoplasms as opposed to total or partial graft nephrectomy.

Keywords: Focal treatment; graft rejection; nephron sparing surgery; renal transplant patients.

Copyright © 2022, Turkish Society for Radiation Oncology
Introduction

The incidence of renal cell carcinoma (RCC) ranges from 0.5% to 1.5% among renal transplant patients[1,2] occurring in the native kidneys or in the allograft. It represents 4.8% of all malignancies in this setting of patients[3] compared to 3% of the general population. Allograft malignancies occur in 0.2–0.34% of renal transplant patients.[2,4,5]

When managing RCC in allograft kidneys, the physician must balance the need for renal preservation with the need of achieving oncologic control. The treatment of choice for RCC in the allograft kidney is surgery, mainly consisting of partial nephrectomy (PN)/nephron sparing surgery (NSS) wherever possible based on tumor and patient characteristics.[1] PN in renal allografts has the advantage of graft preservation with consequential avoidance of hemodialysis.

The increase in the diagnosis of small renal masses discovered incidentally on follow-up imaging led to considering focal and non-surgical treatments such as radiofrequency ablation, cryoablation, microwave ablation, and focal radiotherapy. Ablative therapies, which have been shown to be a safe and effective treatment for small renal masses,[6] are minimally invasive, associated with a low morbidity, and can be performed percutaneously making them well suited for the treatment of RCC in renal allografts. However, little data exist on outcomes after tumor ablation in transplanted kidneys.

The purpose of this systematic review was to define the role of focal approaches such as thermal ablation (TA) (radiofrequency and microwave, cryoablation), interventional radiotherapy (called also brachytherapy), electrochemotherapy, and stereotactic body radiotherapy (ablative radiotherapy), as alternative to nephron-sparing surgery in the treatment of Stage I kidney cancer.

Materials and Methods

A systematic review was carried out and reported according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement guidelines.[7] We defined a Population, Intervention, Comparator, and Outcome (PICO) model to elaborate the specific elements of the question. Table 1 reports PICO model. The primary outcome was graft rejection survival during follow-up.

Search Strategy

The literature search was performed by querying electronic databases (PubMed, Scopus, and Web of Science) using selected keywords linked through Boolean operator “AND” and “OR” to build specific search strings for each electronic engineer (Table 2). The article search was completed manually by screening references from relevant papers and using the snowball search technique.

Selection Process

After duplicates removal, single citations retrieved were screened, reading title and abstract. We extracted potentially relevant abstracts, full-text articles, and those who met the inclusion criteria and considered them for final analysis. Two researchers performed citation screening independently and disagreement will be resolved by discussion or by querying a third researcher. An internal multidisciplinary expert team decided about their inclusion in the review. Finally, an external committee performed an independent check and the final approval of the review.

The eligibility criteria were:

Inclusion criteria

The following criteria were included in the study:

- Kidney transplant recipients with kidney graft neoplasm

Table 1  PICO model

<table>
<thead>
<tr>
<th>PICO</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>Kidney transplant recipient with kidney graft neoplasm</td>
</tr>
<tr>
<td>Intervention</td>
<td>Focal treatment (thermal ablation, radiofrequency, brachytherapy, electrochemotherapy, stereotactic body radiotherapy, and cryoablation)</td>
</tr>
<tr>
<td>Comparator</td>
<td>Graft nephrectomy</td>
</tr>
<tr>
<td>Outcome</td>
<td>Patient overall survival; progression free survival; graft survival; toxicity; and local control</td>
</tr>
<tr>
<td>Time frame</td>
<td>2010-2019</td>
</tr>
</tbody>
</table>

PICO: Population, Intervention, Comparator, and Outcome
Evaluating the use of focal treatment (FT) (TA, radiofrequency, microwave, cryoablation, brachytherapy, electrochemotherapy, and stereotactic body radiotherapy) compared to graft nephrectomy

Evaluating as an outcome patient overall survival (OS); progression free survival; graft survival; toxicity; and local control

English language
Time restriction (2010-2019)
Original article.

Exclusion criteria
Conference paper, doubled publication, survey, letter, editorial, book chapter, and review were excluded from the study.

Data extraction and synthesis
Data from selected full-text studies were extracted by two independent authors. The collected data, including first author, country, year of publication, study design, number of patients, type of developed cancer, treatment features, and main results, were then entered in an electronic sheet and compared between the two authors. In presence of differences, the authors analyzed the article and discussed divergent points. A narrative description of the results was finally performed and discussed with the multidisciplinary team.

Results
The literature search strategy resulted in 331 single citations. After literature screening, 24 records were identified for full-text evaluation. Out of these, 12 were excluded and the reasons for exclusion are reported in Figure 1. Eventually, 10 full-texts were considered eligible and were included in results analysis. Twelve additional articles were included based on subtract evaluation because they were clearly eligible. The flowchart of the studies selection process is described in Figure 1.

Characteristics of the Included Studies
All selected studies were retrospective case-series, performed between 2011 and 2019 in France, USA, Hun-

---

Table 2  Literature search

<table>
<thead>
<tr>
<th>Electronic engineer</th>
<th>Search string</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed</td>
<td>(“Renal transplant” OR “kidney transplant” OR “kidney transplantation” OR “renal transplantation”) AND (metastasis OR metastatic OR metastases OR “cancer” OR neoplasm OR “tumor” OR “cancers” OR “tumors” OR “tumor” OR “tumors” OR neoplasms OR melanoma) AND (“focal treatment” OR thermal ablation OR radiofrequency OR brachytherapy OR electrochemotherapy OR “stereotactic body radiation therapy” OR “stereo body radiotherapy” OR “stereobody radiotherapy” OR “stereotactic radiotherapy” OR SBRT OR cryoablation) Filters: English; 10 years</td>
</tr>
<tr>
<td>Web of Science</td>
<td>ALL=((Renal transplant) OR (kidney transplant) OR (kidney transplantation) OR (renal transplantation)) AND (metastasis OR metastatic OR metastases OR “cancer” OR neoplasm OR tumor OR cancers OR tumors OR tumor OR tumors OR neoplasms OR melanoma) AND (“focal treatment” OR thermal ablation OR radiofrequency OR brachytherapy OR electrochemotherapy OR (stereotactic body radiation therapy) OR (stereo body radiotherapy) OR (stereobody radiotherapy) OR (stereotactic radiotherapy) OR SBRT OR cryoablation)</td>
</tr>
<tr>
<td>Scopus</td>
<td>(“Renal transplant” OR “kidney transplant” OR “kidney transplantation” OR “renal transplantation”) AND (metastasis OR metastatic OR metastases OR “cancer” OR neoplasm OR “tumor” OR “cancers” OR “tumors” OR “tumor” OR “tumors” OR neoplasms OR melanoma) AND (“focal treatment” OR thermal ablation OR radiofrequency OR brachytherapy OR electrochemotherapy OR “stereotactic body radiation therapy” OR “stereo body radiotherapy” OR “stereobody radiotherapy” OR “stereotactic radiotherapy” OR SBRT OR cryoablation) AND (LIMIT-TO (PUBYEAR, 2019) OR LIMIT-TO (PUBYEAR, 2018) OR LIMIT-TO (PUBYEAR, 2017) OR LIMIT-TO (PUBYEAR, 2016) OR LIMIT-TO (PUBYEAR, 2015) OR LIMIT-TO (PUBYEAR, 2014) OR LIMIT-TO (PUBYEAR, 2013) OR LIMIT-TO (PUBYEAR, 2012) OR LIMIT-TO (PUBYEAR, 2011) OR LIMIT-TO (PUBYEAR, 2010) OR LIMIT-TO (PUBYEAR, 2009)) AND (LIMIT-TO (LANGUAGE, “English”))</td>
</tr>
</tbody>
</table>
gary, Canada, Italy, Belgium, Germany, Denmark and Australia. All patients were diagnosed with a kidney graft neoplasm, detected during routine follow-up, and underwent FT (radiofrequency TA, microwave ablation, cryoablation, interventional radiotherapy (IRT, also called brachytherapy), and stereotactic body radiotherapy or partial/total graft nephrectomy. Kidney graft neoplasms approached with FTs were mostly small (<3 cm), unique cortical, or partially exophytic lesions, even though FT of lesions larger than 3cm, as well as of two or more small lesions of the same graft were described. Characteristics of included studies are reported in Table 3.

Twenty studies reported no graft rejection[8-26] while one study showed three graft rejection.[12] Local recurrences were reported in two studies.[17,21]

Christensen and Hansen found a graft neoplasm only 4 days after transplantation, suggesting the donor-origin of the tumor.[11] Pre-treatment biopsy can help to assess the histotype as well as the origin of the neoplasm, as in the case described by Veltri et al., in which Fluorescence In-Situ Hybridization performed on the bioptic sample from the graft neoplasm in a male patient revealed the presence of female sexual chromosomes (XX), likely from the female donor.[26,27]

Végső et al.[25] treated nine patients (five RFA and five nephrectomies) and reported a global 1- and 2-years OS of 83.3% and 66.6%, respectively: The five RFA patients were still alive at follow-up, whereas only 25% of nephrectomy patients was alive.

Guleryuz et al.[18] treated 62 patients conservatively including: 48 by PN and 14 by TA. These patients were compared to 30 other patients who were treated by transplant nephrectomy. Nine patients treated by PN had post-operative complications (21%), including four requiring operative intervention (Clavien IIIb). None of the patients treated by TA had complications. None of the 62 patients required post-treatment dialysis, and all transplants were functional 1 month after the treatment. One patient had a recurrence 23 months after treatment with PN. Specific survival was 100% at the time of last follow-up (median time after treatment 37 months) for patients treated by PN or TA.

In addition, there is a great variability between these various studies on FT protocols, even for the same type of FT (e.g., RFA) and for the same specific manufactur-
### Table 3  Characteristics of included studies

<table>
<thead>
<tr>
<th>Author, year (Country)</th>
<th>Title</th>
<th>Objective</th>
<th>Treatment(s)</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aron, USA (2007) (8)</td>
<td>Percutaneous radiofrequency ablation of tumor in transplanted kidney</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>1 RFA</td>
<td>100% graft and patient survival Viable tumor tissue found at follow-up biopsy, and then retreated with RFA</td>
</tr>
<tr>
<td>Baughman et al., USA (2004)[9]</td>
<td>Computerized tomography guided radio frequency ablation of a renal cell carcinoma within a renal allograft</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>1 RFA</td>
<td>100% graft and patient survival No local recurrence</td>
</tr>
<tr>
<td>Charboneau et al., USA (2002)[10]</td>
<td>Sonographically guided percutaneous radio frequency ablation of a renal cell carcinoma in a transplanted kidney</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>1 RFA</td>
<td>100% graft and patient survival No local recurrence</td>
</tr>
<tr>
<td>Christensen and Hansen, Denmark (2015)[11]</td>
<td>Donor Kidney With Renal Cell Carcinoma Successfully Treated With Radiofrequency Ablation: A Case Report</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>1 RFA</td>
<td>100% graft and patient survival No local recurrence Tumor found 4 days after transplantation</td>
</tr>
<tr>
<td>Cool and Kachura, Canada (2017)[12]</td>
<td>Radiofrequency Ablation of T1a Renal Cell Carcinomas within Renal Transplant Allografts: Oncologic Outcomes and Graft Viability</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>10 patients, 12 RFA</td>
<td>No local recurrence at 54.3 months mean follow-up three graft failure, however, with pre-ablation GFR &lt;30 mL/min/1.73 m^2 one death for comorbidities</td>
</tr>
<tr>
<td>Cornelis et al., France (2011)[13]</td>
<td>De novo renal tumors arising in kidney transplants: Midterm outcome after percutaneous thermal ablation</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>Radiofrequency ablation (n=19) or cryoablation (n=5)</td>
<td>2/27 DIED None of these patients required dialysis following ablative therapy for their tumors No local recurrence</td>
</tr>
<tr>
<td>Elkentaoui et al, France (2010)[14]</td>
<td>Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>2 RFA, 1 partial nephrectomy</td>
<td>100% graft and patient survival No local recurrence</td>
</tr>
<tr>
<td>Goeman et al., Belgium (2006)[16]</td>
<td>Percutaneous ultrasound-guided radiofrequency ablation of recurrent renal cell carcinoma in renal allograft after partial nephrectomy</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>1 RFA</td>
<td>100% graft and patient survival No local recurrence</td>
</tr>
<tr>
<td>Gul et al., 2019 (USA)[17]</td>
<td>Focal Ablative Therapy for Renal Cell Carcinoma in Transplant Allograft Kidneys</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>MWA and IRE</td>
<td>Four patients alive without disease; patient died for stroke and one for infection No patients required dialysis after ablation</td>
</tr>
<tr>
<td>Author, year (Country)</td>
<td>Title</td>
<td>Objective</td>
<td>Treatment(s)</td>
<td>Main results</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>------------------------------------------</td>
<td>---------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Guleryuz et al., 2016 (France)[18]</td>
<td>A national study of kidney graft tumor treatments: Toward ablative therapy</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>48 partial nephrectomy and 14 ablative therapy</td>
<td>No graft was lost when a conservative treatment was performed. Nine patients treated by PN had post-operative complications (21%), including four requiring operative intervention (Clavien IIIb). None of the patients treated by TA had complications. Specific survival was 100% at median FUP of 37 months for patients treated by PN or TA.</td>
</tr>
<tr>
<td>Iezzi et al., Italy (2019)[15]</td>
<td>Radiofrequency thermal ablation of renal graft neoplasms: Case series and literature review</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>3 RFA</td>
<td>100% alive, mean follow-up 15 months. 100% graft survival (mean follow-up 15 months). 100% Complete response.</td>
</tr>
<tr>
<td>Leveridge et al., Canada (2011)[4]</td>
<td>Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients</td>
<td>Patient survival</td>
<td>Three RFA, two partial nephrectomy, three graft nephrectomy</td>
<td>100% graft and patient survival. No local recurrence. One patient underwent repeat renal transplantation due to decreased renal function, which preceded but worsened after RFA of the allograft RCC.</td>
</tr>
<tr>
<td>Olivani et al., Italy (2011)[20]</td>
<td>Percutaneous ultrasound-guided radiofrequency ablation of an allograft renal cell carcinoma: A case report</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>1 RFA</td>
<td>100% graft and patient survival. No local recurrence.</td>
</tr>
<tr>
<td>Ploussard et al., France (2011)[1]</td>
<td>Biopsy-confirmed de novo renal cell carcinoma in renal grafts: A single-centre management experience in a 2396 recipient</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>Two cryoablation, ten nephrectomy/NSS</td>
<td>100% alive (mean FUP 43 months). 100% graft survival. one local recurrence in one NSS.</td>
</tr>
<tr>
<td>Sanchez and Barr, USA (2009)[21]</td>
<td>Contrast-enhanced ultrasound detection and treatment guidance in a renal transplant patient with renal cell carcinoma</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>1 RFA</td>
<td>100% graft and patient survival. No local recurrence.</td>
</tr>
</tbody>
</table>
Conservative treatment can be preferred to nephrectomy, when it is feasible, to avoid a return to dialysis: Among conservative treatments, PN is the treatment of choice for small de novo kidney tumors. On the other side, FTs, which showed short- and mid-term results similar to nephrectomy, can be considered as alternative therapeutic options, and can be performed during conscious sedation, as opposed to general anesthesia of partial/total graft nephrectomy.[18]

Data Synthesis

The studies underlined safety and efficacy of FTs, with low morbidity and good graft survival, but none of them provided a direct comparison with graft NSS. There is still no clear evidence that FTs, and particularly percutaneous ones in particular, are indicated as a standard treatment in kidney graft neoplasms as opposed to total or partial graft nephrectomy.

Table 3

Cont.

<table>
<thead>
<tr>
<th>Author, year (Country)</th>
<th>Title</th>
<th>Objective</th>
<th>Treatment(s)</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Su et al., Australia (2014)[22]</td>
<td>Management of renal masses in transplant allografts at an australian kidney-pancreas transplant unit</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>One RFA, three nephrectomy/NSS</td>
<td>100% alive; 100% graft survival (in RFA e NSS) No recurrence</td>
</tr>
<tr>
<td>Swords et al., USA (2013)[23]</td>
<td>Treatment options for renal cell carcinoma in renal allografts: A case series from a single institution</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>RFA (two tumors, one patient), three nephrectomy/NSS</td>
<td>100% alive; 100% graft survival (RFA and partial nephrectomy)</td>
</tr>
<tr>
<td>Tillou et al., France (2012)[24]</td>
<td>De novo kidney graft tumors: Results from a multicentric retrospective national study</td>
<td>Cancer specific survival rates</td>
<td>Nephrectomy (n=35, 44.3%); Radiofrequency (n=5; 6.3%)</td>
<td>5 years cancer specific survival rate was 94%</td>
</tr>
<tr>
<td>Végső et al., Hungary (2013)[25]</td>
<td>Detection and management of renal cell carcinoma in the renal allograft</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>Five RFA, four nephrectomy</td>
<td>100% alive RFA; 25% alive nephrectomy (3/4 died: cause of death was tumour progression, pneumonia and sepsis) (mean FUP 22.6 months)</td>
</tr>
<tr>
<td>Veltri et al., Italy (2009)[26]</td>
<td>Radiofrequency Thermal Ablation of Small Tumors in Transplanted Kidneys: An Evolving Nephron-sparing Option</td>
<td>Patient and graft survival, treatment efficacy</td>
<td>Three RFA</td>
<td>100% graft survival (RFA) 1 y OS: 83.3%; 2y OS 66.6%</td>
</tr>
</tbody>
</table>

RFA: Radiofrequency ablation; NSS: Nephron-sparing surgery; MWA: Microwave ablation; TA: Thermal ablation; IRE: Irreversible electroporation; GFR: Glomerular filtration rate; FUP: Follow-up; y: Year; OS: Overall survival; RCC: Renal cell carcinoma

Discussion

Ultrasound follow-up of kidney grafts is performed routinely and makes easy to diagnose a Stage I renal cancer.[8] Even though PN is considered the treatment of choice in these patients, some of them might not be eligible for surgery for several reasons (e.g., co-morbidities, tumor site, or histology); in addition, PN would be performed on a non-naive abdominal site which already received graft implant surgery. These patients could likely benefit from a focal approach, which is of great efficacy in small lesions as Stage I renal neoplasms.[8] The present systematic review showed that FTs, which demonstrated short- and mid-term results similar to conventional PN in terms of ablation time (reportedly ranging from 6 to 15 min for lesions smaller than 2 cm), temperature, and number of probes,[19,20] can be preferred to nephrectomy, when it is feasible, to avoid a return to dialysis. Among conservative treatments, PN is the treatment of choice for small de novo kidney tumors. On the other hand, FTs, which showed short- and mid-term results similar to nephrectomy, can be considered as alternative therapeutic options, and can be performed during conscious sedation, as opposed to general anesthesia of partial/total graft nephrectomy, reducing the risks for the patient.[18]
PN, can be considered as a good alternative therapeutic option. FTs can be performed during conscious sedation, as opposed to general anesthesia of partial/total graft nephrectomy, reducing the risks for the patient.

In non-transplanted patients, a systematic review and meta-analysis reported that recurrence-free survival and cancer-specific survival were similar between patients treated with PN and TA.[29] These results oppose a previous meta-analysis in which recurrence-free survival was inferior for RFA and cryoablation when compared with PN, although metastasis-free survival was not significantly different among the treatment groups.[30] Klatte et al.[31] performed a systematic review comparing PN and laparoscopic cryoablation and observed a higher risk of recurrence for cryoablation patients, while metastases-free survival was similar. In case of renal transplant patients, the treatment scenario is more complicated. Due to the low incidence of renal graft neoplasms, most studies on the management of renal tumors in transplant allografts come from case reports and short series, and the interpretation of the literature is burdened by the selection bias related to patients’ age and comorbidities.[32] These observations suggest that further study is warranted.

When planning a FT of a neoplasm arising from the kidney graft, various elements must be taken in consideration: Among these, the complex net of nerves that crosses and connects different pelvic structures, first of all the genitofemoral nerve which is the one particularly exposed to accidental iatrogenic injury.[33] Age is another important factor that must be taken into account when planning a treatment: An old transplant patient with a renal tumor could be treated with a percutaneous approach even when risk of recurrence is not negligible: This approach, although curative, would offer to this old patient more years of renal function.

The decision regarding allograft mass management was based on the desire to maintain adequate renal function, patient preference and competing health risks, and mass characteristics and site. Kidney graft neoplasms management must be carefully and thoroughly discussed at multidisciplinary renal oncology rounds, considering both the need to be as radical as possible, as well as the need to try to preserve renal function and avoid the risk of dialysis, and also taking into account patient’s characteristics and preferences.

**Conclusion**

Even though there is still no clear evidence that FTs are indicated as a standard treatment in kidney graft neoplasms as opposed to total or partial graft nephrectomy, encouraging data come from the analyzed studies. Randomized studies are needed, as well as studies with larger numbers.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** I have no conflict of interest.

**Financial Support:** I have no financial support.

**References**

Posa et al.
Focal Approach in Stage I Cancer Renal Graft


